thiazoles has been researched along with Venous Thromboembolism in 201 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 174 (86.57) | 24.3611 |
| 2020's | 27 (13.43) | 2.80 |
| Authors | Studies |
|---|---|
| Bolek, T; Grilusová, K; Mokáň, M; Samoš, M; Škorňová, I; Staško, J | 1 |
| Bacchiarri, F; Bocchia, M; Calzoni, P; Fineschi, D; Puccetti, L; Sammartano, V; Santoni, A | 1 |
| Arguello Da Silva, J; Bordignon Primieri, G; Oliveira Rocha, M; Ribeiro Wingert, N; Steppe, M | 1 |
| Kato, S; Odajima, S; Okamoto, A; Saito, M; Seki, T; Shoburu, Y; Suzuki, E; Takano, H; Takenaka, M; Tomita, K; Yamada, K | 1 |
| Fukasawa, T; Kawakami, K; Nakashima, M; Seki, T | 1 |
| Chen, S; Gong, DW; Li, JL; Ma, YH; Mai, JL; Wang, HB; Xiao, JC; Zhang, M | 1 |
| Chistolini, A; Foà, R; Santoro, C; Serrao, A | 1 |
| Agnelli, G; Chen, C; Chiu, KM; Choi, WI; Cohen, A; De Caterina, R; Kaburagi, J; Kim, YH; Kirchhof, P; Koretsune, Y; Laeis, P; Nakamura, M; Rauer, H; Reimitz, PE; Thee, U; Unverdorben, M; Wang, CC; Yamashita, T | 1 |
| Büller, HR; Carrier, M; Di Nisio, M; Duggal, A; Gaddh, M; Garcia, D; Grosso, MA; Kakkar, AK; Kraaijpoel, N; Mercuri, MF; Middeldorp, S; Mulder, FI; Raskob, G; Royle, G; Segers, A; Shivakumar, S; van Es, N; Verhamme, P; Wang, T; Weitz, JI; Zhang, G | 1 |
| Marti, C; Righini, M; Robert-Ebadi, H; Rossel, A; Stebler-Fontaine, L | 1 |
| Jimi, S; Kamei, T; Oohata, Y; Takahata, S; Tamura, T | 1 |
| Goto, E; Horinaka, S; Ishimitsu, T; Kato, T | 1 |
| Barillari, G; Bortoluzzi, C; Dentali, F; Giorgi, M; Orabona, R; Pacetti, E; Sciatti, E; Zaffaroni, M | 1 |
| Auditeau, C; Blandinières, A; Gendron, N; Smadja, DM; Talbot, A | 1 |
| Ageno, W; Casella, IB; Chee, KH; Desch, M; Donado, E; Goldhaber, SZ; Reilly, PA; Schellong, S; Schulman, S; Singer, DE; Tang, W; Voccia, I | 1 |
| Eichinger, S; Grosso, MA; Kyrle, PA; Lin, M; Shi, M | 1 |
| Aballi, S; Bergan, J; Fronas, S; Garabet, L; Ghanima, W; Overstad, S; Tjonnfjord, E | 1 |
| Agnelli, G; Ay, C; Bramlage, P; Brüggenjürgen, B; Cohen, AT; Coppens, M; Fronk, EM; Gaine, S; Hainaut, P; Hoffmann, U; Jimenez, D; Laeis, P; Levy, P; Malzer, T; Manu, MC; Reimitz, PE; Schindewolf, M; Zierhut, W | 2 |
| Albertsen, IE; Højen, AA; Larsen, TB; Nielsen, PB; Noble, S; Ording, AG; Overvad, TF; Søgaard, M | 1 |
| Camporese, G; Di Micco, P; Fernández-Capitán, C; Font, C; Monreal, M; Prandoni, P; Rivas, A; Sahuquillo, JC; Simioni, P; Villares, P | 1 |
| Bottino, R; Carbone, A; D'Andrea, A; Golino, P; Liccardo, B; Nigro, G; Papa, AA; Rago, A; Russo, V; Spaccarotella, C | 1 |
| Chan, N; Eikelboom, JW; Sobieraj-Teague, M | 1 |
| Fujitaka, K; Hamai, K; Hongoh, M; Hotta, T; Ishihara, N; Ishikawa, N; Isobe, T; Kobayashi, M; Kubota, T; Nakamura, A; Nishimura, N; Sugisaka, J; Tanino, A; Tsubata, Y; Yamasaki, M | 1 |
| Colonna, P; Fazio, G; Fischetti, A; Mannarini, A; Mazzetti, M; Squizzato, A | 1 |
| Feng, W; Huang, D; Lu, A; Wang, X | 1 |
| Oh, HJ; Park, BJ; Ryu, KH; Yoon, BH | 1 |
| Alexandris-Souphis, T; Ali, MA; Barnes, GD; Decamillo, D; Errickson, J; Froehlich, JB; Haymart, B; Kaatz, S; Kline-Rogers, E; Kong, X; Kozlowski, JH; Krol, GD; Li, Y; Schaefer, JK; Shankar, SR; Sood, SL | 1 |
| Berger, F; Bhatt, MD; Dave, J; Duggal, A; Goldenberg, NA; Grosso, M; Jacobs, JP; Newburger, J; Pandya, G; Portman, MA | 1 |
| Bosch, FTM; Büller, HR; Carrier, M; Di Nisio, M; Duggal, A; Garcia, D; Grosso, MA; Huisman, MV; Kamphuisen, PW; Middeldorp, S; Mulder, FI; Raskob, GE; Segers, A; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Zwicker, JI | 1 |
| Gkiatas, I; Korompilias, AV; Kostas-Agnantis, I; Papadopoulos, DV; Tsantes, AG; Ziara, P | 1 |
| Finks, SW; Gibson, CM | 1 |
| Ito, M; Nakamura, M; Yamada, N | 2 |
| Langer, F; Voigtlaender, M | 1 |
| Cifu, AS; Jain, A | 1 |
| Imberti, D; Mastroiacovo, D | 1 |
| Dentali, F; Fantoni, C | 1 |
| Casson, RJ; Chan, W; Sanders, P; Selva, D; Sun, MT; Wong, CX; Wood, MK | 1 |
| Brown, KS; Grosso, MA; Lin, M; Mercuri, MF; Vandell, AG; Walker, J; Zhang, G | 1 |
| Hashimoto, S; Hayashi, S; Ishida, K; Kodato, K; Kuroda, R; Kurosaka, M; Matsumoto, T; Oka, S; Shibanuma, N; Takayama, K; Toda, A | 1 |
| Davis, DO; Davis, KA | 1 |
| Douxfils, J; Gosselin, RC | 1 |
| Fujimoto, N; Hasegawa, M; Ikejiri, M; Katayama, N; Matsumoto, T; Ohishi, K; Sudo, A; Tone, S; Wada, H; Wakabayashi, H; Watanabe, M; Yamaguchi, T; Yamashita, Y | 1 |
| Arima, Y; Hokimoto, S; Ishii, M; Ito, M; Iwashita, S; Kaikita, K; Mitsuse, T; Mizuta, H; Nakamura, E; Ogawa, H; Oimatsu, Y; Okamoto, N; Sueta, D; Tsujita, K; Yamabe, S | 1 |
| Akamatsu, Y; Hirotomi, K; Kobayashi, H; Kumagai, K; Kusayama, Y; Okuyama, H; Saito, T; Shinohara, K | 1 |
| Chu, XC; Gao, JH; Ning, B; Wang, LL; Zhao, CX | 1 |
| Akaike, M; Amano, R; Fukuda, D; Hara, T; Ise, T; Kadota, M; Kusunose, K; Matsuura, T; Oomichi, Y; Sangawa, T; Sata, M; Soeki, T; Tobiume, T; Torii, Y; Ueno, R; Wakatsuki, T; Yagi, S; Yamada, H; Yamaguchi, K; Yamazaki, H | 1 |
| Beer, TM; Daughety, MM; DeLoughery, TG; Olson, SR; Shatzel, JJ | 1 |
| Ageno, W; Brekelmans, MPA; Büller, HR; Chen, CZ; Cohen, AT; Grosso, MA; Lin, M; Medina, A; Mercuri, MF; Raskob, G; Segers, A; Vanassche, T; Verhamme, P; Weitz, JI; Wells, PS; Winters, SM | 1 |
| Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, MA; Kakkar, AK; Kovacs, MJ; Mercuri, MF; Meyer, G; Raskob, GE; Segers, A; Shi, M; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Yeo, E; Zhang, G; Zwicker, JI | 1 |
| Ageno, W; Brekelmans, MPA; Büller, HR; Chen, CZ; Cohen, AT; Grosso, MA; Medina, AP; Mercuri, MF; Raskob, GE; Segers, A; Vanassche, T; Verhamme, P; Weitz, JI; Wells, PS; Winters, SM; Zhang, G | 1 |
| Hu, Y; Tang, L; Zhang, Z | 1 |
| Franco Moreno, AI; García Navarro, MJ; Martín Díaz, RM | 1 |
| Bleker, SM; Brekelmans, MPA; Büller, HR; Cohen, AT; Eerenberg, ES; Kraaijpoel, N; Middeldorp, S; Raskob, GE; van Es, N | 1 |
| Arya, R; Chitongo, PB; Dighe, P; Patel, JP; Patel, RK; Roberts, LN; Vadher, B | 1 |
| Asahina, H; Furuta, M; Goudarzi, H; Ikezawa, Y; Kikuchi, E; Kikuchi, H; Kikuchi, J; Mizugaki, H; Nishimura, M; Sakakibara-Konishi, J; Shinagawa, N; Shoji, T; Takashima, Y; Tsujino, I | 1 |
| Ginsberg, JS; Hirsh, J | 1 |
| Howard, LS | 1 |
| Koscielny, J; Rosenthal, C; von Heymann, C | 1 |
| Badreldin, H | 1 |
| Eguchi, M; Ikeda, S; Kawano, H; Koga, S; Koide, Y; Maemura, K; Muroya, T; Sato, D; Tsuneto, A; Yamagata, Y; Yonekura, T; Yoshimuta, T | 1 |
| Egawa, T; Izushi, Y; Kiuchi, T; Sato, T; Shimada, K; Shiota, N; Takami, Y; Takuma, R; Tetsunaga, T | 1 |
| Abdel-Razeq, H; Finianos, A; Taher, AT | 1 |
| Myers, B | 1 |
| Ageno, W; Ay, C; Blondon, M; Brekelmans, M; Büller, HR; Delluc, A; Eichinger, S; Hutten, BA; Klok, FA; Middeldorp, S; Scheres, L; Schreiber, K; Stach, K | 1 |
| Fiorelli, EM; Rossi, RE | 1 |
| Linkins, LA | 1 |
| Büller, HR; Raskob, GE; Segers, A | 1 |
| Calabrò, MG; Curigliano, G | 1 |
| Hironaka, S | 1 |
| Nasser, NJ | 1 |
| Dufilho, M; Frere, C | 1 |
| Carrier, M; Khorana, AA; Lee, AYY; Meyer, G; Noble, S; O'Connell, C; Soff, G | 1 |
| Beyer-Westendorf, J; Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, M; Hernandez, CR; Kakkar, AK; Kraaijpoel, N; Mercuri, MF; Middeldorp, S; Mulder, FI; Raskob, GE; Santamaria, A; Schwocho, L; Segers, A; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Zhang, G; Zwicker, JI | 1 |
| Adam, TJ; Alonso, A; Lutsey, PL; MacLehose, RF; Roetker, NS; Zakai, NA | 1 |
| Di Nisio, M | 1 |
| Eguchi, M; Ikeda, S; Kawano, H; Koga, S; Koide, Y; Maemura, K; Sato, D; Tsuneto, A; Yamagata, Y; Yonekura, T; Yoshimuta, T | 1 |
| Hashimoto, S; Hayashi, S; Ishida, K; Kodato, K; Kuroda, R; Kurosaka, M; Matsumoto, T; Matsushita, T; Niikura, T; Sasaki, H; Shibanuma, N; Takayama, K; Toda, A | 1 |
| Aguiar, VCR; Casella, IB; Fareed, J; Júnior, VC; Ramacciotti, E; Zerati, AE | 1 |
| Själander, A; Själander, S | 1 |
| Ageno, W; Agnelli, G; Chan, NC; De Caterina, R; Diener, HC; Hylek, E; Lip, GYH; Raskob, GE; Siegal, DM; Verheugt, FWA; Weitz, JI | 1 |
| Ebato, M; Higashino, M; Hozumi, T; Kogo, M; Matsui, M; Nakamura, S; Sasaki, T; Shimizu, T; Sunaga, T; Suzuki, H; Takahashi, N; Watanabe, T | 1 |
| Becattini, C; Giustozzi, M; Vedovati, MC | 1 |
| Fujitaka, K; Hamada, H; Hattori, N; Horimasu, Y; Iwamoto, H; Masuda, T; Miyamoto, S; Nakao, S; Nakashima, T; Sakamoto, S; Yamaguchi, K | 1 |
| Oo, TH; Rojas-Hernandez, CM | 1 |
| Carrier, M; Kimpton, M | 1 |
| Honda, Y; Morishima, Y | 1 |
| Fujimoto, E; Kagawa, K; Sata, M; Yagi, S | 1 |
| Asamura, T; Nakamura, M; Shiosakai, K; Uchino, K; Yamada, N | 1 |
| Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J | 1 |
| Chen, H; Deng, Y; Li, S; Tong, Y; Zou, L | 1 |
| Hasegawa, K; Miyazaki, Y; Morimoto, T; Sase, K | 1 |
| Dalla Valle, F; Pesavento, R; Piovella, C; Prandoni, P; Tormene, D | 1 |
| Büller, H; Mercuri, M; Prins, M; Raskob, G; Schwocho, L; Segers, A; Shi, M; van Kranen, R | 1 |
| Spyropoulos, AC; Turpie, AG | 1 |
| Agnelli, G; Becattini, C; Franco, L | 1 |
| Ishida, K; Kuroda, R; Kurosaka, M; Matsumoto, T; Sasaki, H; Shibanuma, N; Tateishi, H; Tei, K; Toda, A; Yamashiro, Y | 1 |
| Hirayama, C; Hotoda, H; Kuroda, Y; Nishikawa, Y; Nishiwaki, A | 1 |
| Sprynger, M | 1 |
| Dekkers, OM; den Exter, PL; Huisman, MV; Klok, FA; Kooiman, J; van der Hulle, T | 1 |
| Schulman, S | 1 |
| Arellano-Rodrigo, E; Diaz-Ricart, M; Escolar, G; Galán, AM | 1 |
| Bounameaux, H; Fontana, P; Goldhaber, SZ | 1 |
| Yorozu, T | 1 |
| Cohen, AT; Imfeld, S; Rider, T | 1 |
| Prandoni, P; Taher, A; Temraz, S | 1 |
| Beer, JH; Holy, EW | 1 |
| Gross, PL; Weitz, JI; Yeh, CH | 1 |
| Kakkos, SK; Kirkilesis, GI; Tsolakis, IA | 3 |
| Büller, HR; Coppens, M; Middeldorp, S; Schulman, S; van Es, N | 1 |
| Bounameaux, H; Camm, AJ | 1 |
| Gómez-Outes, A; Lecumberri, R; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Fuji, T; Fujita, S; Kawai, Y; Kimura, T; Tachibana, S; Wang, CJ | 1 |
| Amin, A; Graham, J; Jing, Y; Lin, J; Lingohr-Smith, M; Trocio, J | 1 |
| Hunt, BJ; Sciascia, S | 1 |
| Giugliano, RP; Plitt, A | 1 |
| Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S | 1 |
| Dobesh, PP; Fanikos, J | 1 |
| Ageno, W; Beyer-Westendorf, J | 1 |
| Baber, U; Mastoris, I; Mehran, R | 1 |
| Peerlinck, K; Vanassche, T; Vandenbriele, C; Verhamme, P | 1 |
| Giannoukas, AD; Spanos, K | 1 |
| Amin, A; Bruno, A; Lin, J; Lingohr-Smith, M; Trocio, J | 1 |
| Arepally, GM; Ortel, TL | 1 |
| Cuker, A; Husseinzadeh, H | 1 |
| Ansell, JE; Cabral, KP | 1 |
| Bacchus, F; Schulman, S | 1 |
| Bonfanti, C; Franchini, M; Lippi, G | 1 |
| Agnelli, G; Prandoni, P; Verso, M | 1 |
| Bass, AR | 1 |
| Armbruster, AL; Minor, C; Tellor, KB | 1 |
| Handa, A; Hurst, KV; Lee, R; Milosevic, I | 1 |
| Barrios, V; Escobar, C | 2 |
| Lip, GY; Proietti, M | 2 |
| Ge, D; Morrill, AM; Willett, KC | 1 |
| Abe, K; Büller, H; Kimura, T; Lee, LH; Mercuri, M; Miyazaki, K; Nakamura, M; Oh, D; Segers, A; Wang, C; Wang, YQ; Yin, WH | 1 |
| Drambarean, B; Hellenbart, E; Lee, J; Nutescu, EA | 1 |
| Kawaguchi, M; Konuma, S; Nehashi, Y; Okuda, Y; Uchimura, N | 1 |
| Goldenberg, NA; Kittelson, JM; Massicotte, MP; Takemoto, CM; Yee, DL | 1 |
| Ageno, W; Bauersachs, R; Couturaud, F; Décousus, H; Mismetti, P | 1 |
| Goldhaber, SZ; Kwong, WJ; Preblick, R; White, RH | 1 |
| Brekelmans, M; Coppens, M; Middeldorp, S | 1 |
| Gonzalez, MG; Levy, PD; Peacock, WF; Than, M | 1 |
| Kesteven, P; McCaslin, JE; Robertson, L | 1 |
| Gosavi, S; Mukherjee, D; Switzer, MP; Wani, P | 1 |
| Batson, S; Bird, A; Cohen, AT; Hamilton, M; Liu, X; Mitchell, SA; Phatak, H; Tushabe, D | 1 |
| Dobesh, PP; Finks, SW; Trujillo, TC | 1 |
| Boehlen, F; Bounameaux, H; Fontana, P; Righini, M; Robert-Ebadi, H | 1 |
| Choi, HK; Dalal, DS; Dubreuil, M; Felson, DT; Lee, T; Lu, N; Zhang, Y | 1 |
| Akamatsu, Y; Aratake, M; Ishigatsubo, R; Kobayashi, A; Kobayashi, H; Kumagai, K; Kusayama, Y; Mitsuhashi, S; Saito, T | 1 |
| Bauersachs, R; Bleker, SM; Boda, Z; Brekelmans, MP; Büller, HR; Choi, Y; Cohen, AT; Gallus, A; Grosso, MA; Middeldorp, S; Oh, D; Raskob, G; Schwocho, L | 1 |
| Pan, EY; Sobieraj, DM | 1 |
| Loffredo, L; Perri, L; Violi, F | 1 |
| Agnelli, G; Becattini, C | 1 |
| Hunt, BJ; Levy, JH | 1 |
| Ageno, W; Brekelmans, MP; Büller, HR; Cohen, AT; Grosso, MA; Lin, M; Meyer, G; Raskob, G; Segers, A; Verhamme, P; Weitz, JI; Wells, PS; Winters, SM | 1 |
| Alves Júnior, JL; Fernandes, CJ; Gavilanes, F; Morinaga, LK; Prada, LF; Souza, R | 1 |
| Brown, D; Grace, Y; Guirguis, E; Henningfield, S; Patel, D | 1 |
| Kaminskas, E; Reiffel, JA; Reilly, P; Sager, P; Sarich, T; Seltzer, J; Weitz, JI | 1 |
| Muro, M; Yamada, E; Yoshioka, T | 1 |
| Ageno, W; Brekelmans, MP; Buller, H; Cohen, AT; Grosso, MA; Meyer, G; Raskob, G; Segers, A; Verhamme, P; Weitz, JI; Wells, PS; Zhang, G | 1 |
| Noble, SI | 1 |
| Angchaisuksiri, P; Boda, Z; Büller, HR; Gudz, I; Lanz, H; Lyons, RM; Meijer, K; Mercuri, MF; Oh, D; Raskob, GE; Segers, A; van Es, N; Weitz, JI; Zhang, G | 1 |
| Handa, A; Hurst, KV; O'Callaghan, JM | 1 |
| Barco, S | 1 |
| Ageno, W; Beenen, LF; Brekelmans, MP; Brenner, B; Buller, HR; Chen, CZ; Cohen, AT; Grosso, MA; Meyer, G; Raskob, G; Segers, A; Vanassche, T; Verhamme, P; Weitz, JI; Wells, PS; Zhang, G | 1 |
| Jaffer, IH; Weitz, JI | 1 |
| Davies, AH; Lim, CS; Ravikumar, R | 1 |
| Beyer-Westendorf, J; Hauswald-Dörschel, S; Marten, S; Michalski, F; Tittl, L | 1 |
| Koyfman, A; Long, B | 1 |
| AlEmad, H; AlHajri, L; AlKitbi, N; AlMahri, K; AlMahri, M; Jabbari, S | 1 |
| Baig, U; David, T; Poulakos, M; Walker, JN | 1 |
| Büller, HR; Cohen, A; Di Nisio, M; Grosso, MA; Raskob, G; Winters, SM; Zhang, G | 1 |
| Burkart, T; Rao, PSS | 1 |
| Ageno, W; Becattini, C; D'Angelo, A; Davì, G; De Cristofaro, R; Dentali, F; Di Minno, G; Falanga, A; Gussoni, G; Masotti, L; Palareti, G; Pignatelli, P; Prisco, D; Santi, RM; Santilli, F; Silingardi, M; Tufano, A; Violi, F | 1 |
| Ageno, W; Agnelli, G; Boriani, G; Colonna, P; De Caterina, R; Ghirarduzzi, A; Patti, G; Rossini, R; Rubboli, A; Schinco, P | 1 |
| Bhagirath, VC; Eikelboom, JW; Monagle, S; Ng, KH | 1 |
| Weitz, JI | 2 |
| EncisoSilva, J; Greenberg, B; Schlueter, M; Thomas, I | 1 |
| Ay, C; Dieplinger, B; Domanovits, H; Fries, D; Gary, T; Rohla, M; Vosko, MR; Weiss, TW | 1 |
| Barco, S; Klok, FA; Konstantinides, SV | 1 |
| Bocanegra, T; Cohen, AT; Eriksson, BI; Puskas, D; Raskob, G; Shi, M; Weitz, JI | 1 |
| Fuji, T; Fujita, S; Kawai, Y; Tachibana, S | 1 |
| Keltai, K; Keltai, M | 1 |
| Giugliano, RP; Partida, RA | 1 |
| Cohen, AT | 1 |
| Halim, AB; He, L; Lee, F; Matsushima, N; Mendell, J; Worland, V; Zahir, H; Zhang, G | 1 |
| Green, M; Kastrissios, H; Mendell, J; Patel, I; Rohatagi, S; Salazar, DE; Shi, M | 1 |
| Kaatz, S; Mahan, CE | 1 |
| Martin, EN; Money, SR; Shamoun, FE | 1 |
| Graff, J; Harder, S | 1 |
94 review(s) available for thiazoles and Venous Thromboembolism
| Article | Year |
|---|---|
Cancer-associated thrombosis - treatment and prevention with direct oral factor Xa inhibitors.
Topics: Administration, Oral; Factor Xa Inhibitors; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis; Venous Thromboembolism | 2021 |
Efficacy of edoxaban for the treatment of gynecological cancer-associated venous thromboembolism: analysis of Japanese real-world data.
Topics: Administration, Oral; Anticoagulants; Heparin; Humans; Japan; Neoplasms; Pulmonary Embolism; Pyridines; Thiazoles; Venous Thromboembolism | 2022 |
Short-term efficacy and safety of edoxaban for venous thromboembolism after total hip or knee arthroplasty: a systematic review and meta-analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Hemorrhage; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2022 |
[Direct oral anticoagulants in the treatment of cancer-associated thrombosis].
Topics: Administration, Oral; Anticoagulants; Dalteparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyridines; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2019 |
[The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020].
Topics: Anticoagulants; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasm Proteins; Neoplasms; Pyrazoles; Pyridines; Pyridones; Recurrence; Rivaroxaban; Secondary Prevention; Thiazoles; Thrombosis; Venous Thromboembolism | 2020 |
Cancer-associated venous thromboembolism and the non-vitamin K antagonist oral anticoagulants: a review of clinical outcomes and patient perspectives.
Topics: Administration, Oral; Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2020 |
Direct oral anticoagulants: evidence and unresolved issues.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2020 |
Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2021 |
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Network Meta-Analysis; Observational Studies as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2021 |
The role of new oral anticoagulants in orthopaedics: an update of recent evidence.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Tests; Dabigatran; Factor Xa; Hemorrhage; Humans; Orthopedic Procedures; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Topics: Administration, Oral; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2017 |
Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan.
Topics: Administration, Oral; Anticoagulants; Clinical Trials as Topic; Factor Xa Inhibitors; Hemorrhage; Hospitalization; Humans; Japan; Neoplasms; Outpatients; Platelet Count; Pyrazoles; Pyridines; Pyridones; Recurrence; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Topics: Acute Disease; Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; Long-Term Care; Neoplasms; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2017 |
Risk of Intraocular Bleeding With Novel Oral Anticoagulants Compared With Warfarin: A Systematic Review and Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Eye Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis.
Topics: Anticoagulants; Arthroplasty; Azetidines; Benzylamines; Dabigatran; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Network Meta-Analysis; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism; Warfarin | 2017 |
Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide.
Topics: Androgen Receptor Antagonists; Anticoagulants; Atrial Fibrillation; Benzamides; Dabigatran; Drug Interactions; Embolism; Heart Valve Prosthesis; Heparin, Low-Molecular-Weight; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Progress in the research on venous thromboembolism.
Topics: Anticoagulants; Blood Coagulation Factors; Computed Tomography Angiography; Dabigatran; Genetic Predisposition to Disease; Heparin; Humans; Phlebography; Practice Guidelines as Topic; Pulmonary Embolism; Pyridines; Quality of Life; Recurrence; Risk Factors; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2017 |
Direct oral anticoagulants: An update.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Venous Thromboembolism; Withholding Treatment | 2018 |
Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2018 |
Update on Direct Oral AntiCoagulants (DOACs).
Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Interactions; Drug Substitution; Heparin, Low-Molecular-Weight; Humans; Kidney Function Tests; Liver Function Tests; Metabolic Clearance Rate; Perioperative Care; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Dalteparin; Gastrointestinal Neoplasms; Humans; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Venous Thromboembolism | 2018 |
Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism.
Topics: Heparin, Low-Molecular-Weight; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2018 |
Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide.
Topics: Humans; Latin America; Practice Guidelines as Topic; Pyridines; Thiazoles; Venous Thromboembolism | 2018 |
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Atrial Fibrillation; Benzamides; Biomarkers; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Drug Administration Schedule; Factor Xa; Heart Diseases; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Risk; Rivaroxaban; Stroke; Thiazoles; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2019 |
Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
Topics: Anticoagulants; Clinical Trials as Topic; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyridines; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2019 |
Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials.
Topics: Administration, Oral; Anticoagulants; Benzamides; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2019 |
Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism.
Topics: Factor Xa Inhibitors; Hemorrhage; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2019 |
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2019 |
New anticoagulants for the treatment of venous thromboembolism.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; Biotin; Dabigatran; Humans; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Thiazoles; Venous Thromboembolism; Vitamin K | 2013 |
Venous thromboembolism management: where do novel anticoagulants fit?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor X; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
New oral anticoagulants for the treatment of venous thromboembolism.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
New oral anticoagulant agents - general features and outcomes in subsets of patients.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2014 |
The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism.
Topics: Administration, Oral; Animals; Anticoagulants; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Venous Thromboembolism | 2014 |
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
Topics: Acute Disease; Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Long-Term Care; Morpholines; Perioperative Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
[Prevention of venous thromboembolism and anticoagulant therapy].
Topics: Anesthesia, Epidural; Anticoagulants; Biomarkers; Diagnostic Imaging; Fibrin Fibrinogen Degradation Products; Heparin; Humans; Intraoperative Complications; Perioperative Care; Postoperative Complications; Practice Guidelines as Topic; Pulmonary Embolism; Pyridines; Risk Factors; Thiazoles; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2014 |
Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results.
Topics: Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Outcome Assessment, Health Care; Patient Acuity; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2014 |
Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Half-Life; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K | 2014 |
Direct oral anticoagulants in the management of venous thromboembolism--evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Evolving use of new oral anticoagulants for treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2014 |
Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K | 2014 |
Edoxaban: an update on the new oral direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Atrial Fibrillation; Clinical Trials as Topic; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2014 |
Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Target-specific oral anticoagulants: practice issues for the clinician.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Patient Safety; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2015 |
New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Heparin; Humans; Male; Orthopedic Procedures; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thromboembolism; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2015 |
Balancing ischaemia and bleeding risks with novel oral anticoagulants.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2015 |
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2015 |
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.
Topics: Drug Monitoring; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2015 |
The role of factor Xa inhibitors in venous thromboembolism treatment.
Topics: Animals; Blood Coagulation; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2015 |
Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism.
Topics: Administration, Oral; Animals; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism | 2015 |
Cancer-associated thrombosis: investigating the role of new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Recurrence; Thiazoles; Thrombin; Venous Thromboembolism | 2015 |
Using new oral anticoagulants in patients undergoing major orthopedic surgery.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Orthopedic Procedures; Postoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Edoxaban, a Novel Oral Factor Xa Inhibitor.
Topics: Atrial Fibrillation; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Venous Thromboembolism | 2015 |
Current management of venous thromboembolism in Japan: Current epidemiology and advances in anticoagulant therapy.
Topics: Anticoagulants; Fondaparinux; Heparin; Humans; Japan; Polysaccharides; Pulmonary Embolism; Pyridines; Quality of Life; Risk Factors; Thiazoles; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2015 |
Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.
Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Clinical Trials as Topic; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Venous Thromboembolism | 2015 |
Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Dosing of Target-Specific Oral Anticoagulants in Special Populations.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Humans; Kidney Diseases; Liver Diseases; Obesity; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Treatment of pulmonary embolism.
Topics: Antithrombins; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2015 |
Target-specific Oral Anticoagulants in the Emergency Department.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Blood Coagulation Tests; Dabigatran; Drug Interactions; Drug Monitoring; Emergency Service, Hospital; Factor Xa Inhibitors; Hemorrhage; Humans; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2016 |
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2015 |
Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy.
Topics: Administration, Oral; Chemistry, Pharmaceutical; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Molecular Structure; Pyridines; Thiazoles; Venous Thromboembolism | 2015 |
Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism | 2015 |
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Interactions; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2016 |
Direct oral anticoagulants: a guide for daily practice.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2016 |
Edoxaban in venous thromboembolism and stroke prevention: an appraisal.
Topics: Administration, Oral; Animals; Anticoagulants; Antidotes; Atrial Fibrillation; Blood Coagulation; Coagulants; Hemorrhage; Humans; Pyridines; Recurrence; Risk Factors; Stroke; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2016 |
Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Interactions; Humans; Outpatients; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2016 |
Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Sex Characteristics; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2016 |
Treatment of Venous Thromboembolism With New Anticoagulant Agents.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heparin, Low-Molecular-Weight; Humans; Infusions, Intravenous; Male; Middle Aged; Phlebography; Prognosis; Pulmonary Embolism; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Severity of Illness Index; Survival Analysis; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2016 |
Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
Topics: Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Venous Thromboembolism | 2016 |
New anticoagulants for the treatment of venous thromboembolism.
Topics: Anticoagulants; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Time Factors; Venous Thromboembolism; Warfarin | 2016 |
Establishing Edoxaban's Role in Anticoagulation.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2016 |
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank.
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Atrial Fibrillation; Congresses as Topic; Dabigatran; Drug Monitoring; Factor Xa; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Piperazines; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Thrombin Time; Venous Thromboembolism | 2016 |
Risk impact of edoxaban in the management of stroke and venous thromboembolism.
Topics: Administration, Oral; Atrial Fibrillation; Blood Coagulation; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Risk Factors; Stroke; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2016 |
Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Clinical Trials, Phase III as Topic; Coagulants; Dabigatran; Humans; Patient Safety; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2016 |
The Role of New Oral Anticoagulants (NOACs) in Cancer Patients.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Catheters, Indwelling; Dabigatran; Drug Administration Schedule; Drug Dosage Calculations; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2017 |
Best Clinical Practice: Current Controversies in Pulmonary Embolism Imaging and Treatment of Subsegmental Thromboembolic Disease.
Topics: Anticoagulants; Dabigatran; Decision Making; Humans; Patient Outcome Assessment; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Tomography, X-Ray Computed; Venous Thromboembolism | 2017 |
The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
Topics: Administration, Oral; Drug Administration Schedule; Factor Xa Inhibitors; Hemorrhage; Humans; Orthopedic Procedures; Patient Safety; Pyridines; Risk Factors; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2017 |
Edoxaban: A direct oral anticoagulant.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Advances in oral anticoagulation therapy - What's in the pipeline?
Topics: Administration, Oral; Animals; Azepines; Benzamides; Blood Coagulation; Drug Discovery; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide.
Topics: Age Factors; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Humans; Medication Therapy Management; Practice Guidelines as Topic; Pyridines; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Clinical implications of reversal agents for direct oral anticoagulants.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
Reversal of Direct Oral Anticoagulants: Current Status and Future Directions.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa; Forecasting; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2017 |
Anticoagulation Therapy and NOACs in Heart Failure.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
[Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Venous Thromboembolism | 2018 |
Edoxaban tosylate.
Topics: Animals; Clinical Trials as Topic; Factor Xa; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Venous Thromboembolism | 2011 |
Long-term benefits of preventing venous thromboembolic events.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Follow-Up Studies; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2012 |
Performance of new anticoagulants for thromboprophylaxis in patients undergoing hip and knee replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Societies, Medical; Thiazoles; Thiophenes; Venous Thromboembolism | 2012 |
The novel anticoagulants: the surgeons' prospective.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surgical Procedures, Operative; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Topics: Absorption; Anticoagulants; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Liver Diseases; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Tissue Distribution; Venous Thromboembolism | 2013 |
31 trial(s) available for thiazoles and Venous Thromboembolism
| Article | Year |
|---|---|
ENNOBLE-ATE trial: an open-label, randomised, multi-centre, observational study of edoxaban for children with cardiac diseases at risk of thromboembolism.
Topics: Adult; Anticoagulants; Child; Heart Diseases; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2021 |
Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban.
Topics: Anticoagulants; Case-Control Studies; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Pyridines; Retrospective Studies; Risk Factors; Thiazoles; Venous Thromboembolism | 2021 |
Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Cytochrome P-450 CYP2C9; Double-Blind Method; Drug Monitoring; Factor Xa Inhibitors; Female; Genetic Predisposition to Disease; Hemorrhage; Humans; Male; Middle Aged; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Pyridines; Risk Assessment; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism; Vitamin K Epoxide Reductases; Warfarin | 2017 |
Monitoring of hemostatic abnormalities in major orthopedic surgery patients treated with edoxaban by APTT waveform.
Topics: Aged; Drug Monitoring; Hemorrhage; Humans; Male; Middle Aged; Orthopedic Procedures; Partial Thromboplastin Time; Pyridines; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
Edoxaban Enhances Thromboprophylaxis by Physiotherapy After Total Knee Arthroplasty - The Randomized Controlled ESCORT-TKA Trial.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Combined Modality Therapy; Female; Humans; Incidence; Male; Middle Aged; Physical Therapy Modalities; Postoperative Complications; Pyridines; Thiazoles; Thrombosis; Venous Thromboembolism | 2018 |
Edoxaban is effective in reducing the incidence of asymptomatic phlebographic events following closed-wedge high tibial osteotomy.
Topics: Aged; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Humans; Male; Middle Aged; Osteotomy; Partial Thromboplastin Time; Phlebography; Postoperative Complications; Postoperative Period; Prospective Studies; Pyridines; Thiazoles; Tibia; Tomography, X-Ray Computed; Venous Thromboembolism; Venous Thrombosis | 2017 |
Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
Topics: Adult; Aged; Ambulatory Care; Anticoagulants; Double-Blind Method; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyridines; Thiazoles; United States; Venous Thromboembolism; Warfarin | 2017 |
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms; Pyridines; Recurrence; Thiazoles; Venous Thromboembolism | 2018 |
Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial.
Topics: Age Factors; Aged; Aged, 80 and over; Comorbidity; Double-Blind Method; Female; Humans; Male; Polypharmacy; Pyridines; Thiazoles; Venous Thromboembolism | 2018 |
Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients.
Topics: Aged; Anticoagulants; Blood Transfusion; Double-Blind Method; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Odds Ratio; Prospective Studies; Pyridines; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2018 |
Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study.
Topics: Adult; Anticoagulants; Double-Blind Method; Female; Humans; Middle Aged; Pyridines; Thiazoles; Treatment Outcome; Uterine Hemorrhage; Venous Thromboembolism; Warfarin | 2018 |
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Topics: Aged; Anticoagulants; Clinical Decision-Making; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Patient Selection; Pyridines; Recurrence; Risk Assessment; Risk Factors; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism | 2018 |
A prospective randomized comparative study to determine appropriate edoxaban administration period, to prevent deep vein thromboembolism in patients with total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Arthritis; Arthroplasty, Replacement, Knee; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Prospective Studies; Pyridines; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
Safety and Effectiveness of Edoxaban in Japanese Patients With Venous Thromboembolism - An Interim Analysis of Data From a Japanese Postmarketing Observational Study (ETNA-VTE-Japan).
Topics: Aged; Aged, 80 and over; Female; Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Pyridines; Thiazoles; Venous Thromboembolism | 2019 |
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
Topics: Aged; Blood Coagulation; Dalteparin; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Neoplasms; Prospective Studies; Pulmonary Embolism; Pyridines; Recurrence; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2019 |
Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Clinical Protocols; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Predictive Value of Tests; Pyridines; Research Design; Secondary Prevention; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
[Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
Topics: Anticoagulants; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Venous Thromboembolism; Warfarin | 2013 |
Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.
Topics: Aged; Antithrombins; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Japan; Male; Middle Aged; Pyridines; Taiwan; Thiazoles; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2014 |
Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Asia, Eastern; Asian People; Double-Blind Method; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Pulmonary Embolism; Pyridines; Recurrence; Therapeutic Equivalency; Thiazoles; Venous Thromboembolism; Venous Thrombosis; Vitamin K; Warfarin; Young Adult | 2015 |
The use of factor Xa inhibitors following opening-wedge high tibial osteotomy for venous thromboembolism prophylaxis.
Topics: Aged; Antithrombin III; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Male; Osteotomy; Peptide Hydrolases; Postoperative Complications; Prospective Studies; Prothrombin Time; Pyridines; Thiazoles; Tibia; Venous Thromboembolism | 2017 |
Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
Topics: Administration, Oral; Anticoagulants; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Risk Factors; Thiazoles; Venous Thromboembolism; Vitamin K; Warfarin | 2016 |
Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
Topics: Adult; Aged; Anticoagulants; Comparative Effectiveness Research; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Heparin; Humans; Male; Middle Aged; Pulmonary Embolism; Pyridines; Recurrence; Risk Assessment; Secondary Prevention; Thiazoles; Venous Thromboembolism; Ventricular Dysfunction, Right; Warfarin | 2016 |
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
Topics: Adult; Aged; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyridines; Thiazoles; Venous Thromboembolism; Warfarin | 2016 |
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Topics: Aged; Double-Blind Method; Equivalence Trials as Topic; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Prognosis; Pyridines; Survival Rate; Thiazoles; Venous Thromboembolism | 2016 |
Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
Topics: Adolescent; Adult; Aged; Anticoagulants; Double-Blind Method; Equivalence Trials as Topic; Europe; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Pulmonary Embolism; Pyridines; Recurrence; Survival Rate; Thiazoles; Venous Thromboembolism; Ventricular Dysfunction, Right; Warfarin; Young Adult | 2016 |
Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
Topics: Aged; Anticoagulants; Blood Coagulation; Decision Support Techniques; Double-Blind Method; Factor Xa Inhibitors; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Predictive Value of Tests; Pyridines; Risk Assessment; Risk Factors; Thiazoles; Treatment Outcome; Venous Thromboembolism; Vitamin K; Warfarin | 2017 |
External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism.
Topics: Aged; Anticoagulants; Disease Progression; Female; Hemorrhage; Humans; Male; Middle Aged; Odds Ratio; Predictive Value of Tests; Prognosis; Pyridines; Research Design; Risk; Surveys and Questionnaires; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Canada; Dalteparin; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Europe; Factor Xa; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Subcutaneous; Logistic Models; Male; Middle Aged; Phlebography; Pulmonary Embolism; Pyridines; Risk Assessment; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; United States; Venous Thromboembolism; Venous Thrombosis | 2010 |
A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Dose-Response Relationship, Drug; Double-Blind Method; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Japan; Middle Aged; Placebos; Pyridines; Thiazoles; Venous Thromboembolism | 2010 |
Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.
Topics: Adult; Blood Coagulation Tests; Chromatography, Liquid; Drug Interactions; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male; Mass Spectrometry; Pyridines; Thiazoles; Thrombin; Venous Thromboembolism | 2012 |
Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Bayes Theorem; Factor Xa Inhibitors; Humans; Models, Biological; Postoperative Complications; Postoperative Hemorrhage; Pyridines; Thiazoles; Venous Thromboembolism | 2012 |
76 other study(ies) available for thiazoles and Venous Thromboembolism
| Article | Year |
|---|---|
Real-life experience of edoxaban treatment for venous thromboembolism (VTE)/pulmonary embolism (PE) in patients with isolated positive Lupus Anticoagulant (LAC) during the COVID-19 pandemic lockdown in Italy.
Topics: Adult; COVID-19; Factor Xa Inhibitors; Female; Humans; Italy; Lupus Coagulation Inhibitor; Male; Middle Aged; Pandemics; Pulmonary Embolism; Pyridines; Quarantine; Thiazoles; Venous Thromboembolism | 2022 |
Development and validation of capillary zone electrophoresis and high-performance liquid chromatography methods for the determination of oral anticoagulant edoxaban in pharmaceutical tablets.
Topics: Anticoagulants; Chromatography, High Pressure Liquid; COVID-19; Electrophoresis, Capillary; Humans; Pyridines; Reproducibility of Results; SARS-CoV-2; Tablets; Thiazoles; Venous Thromboembolism | 2022 |
Comparative effectiveness and safety of edoxaban, rivaroxaban, and apixaban in patients with venous thromboembolism: A cohort study.
Topics: Anticoagulants; Cohort Studies; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2022 |
Use of edoxaban for the treatment of venous thromboembolism in HIV-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; HIV Infections; Humans; Male; Middle Aged; Pyridines; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2020 |
The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design.
Topics: Atrial Fibrillation; Databases, Factual; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2019 |
Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study.
Topics: Anticoagulants; Humans; Neoplasm Recurrence, Local; Pyridines; Thiazoles; Venous Thromboembolism | 2020 |
[Successful Management of Deep Vein Thromboembolism and Pulmonary Embolism by Edoxaban for Long-Term 5-FU-Based Chemotherapy for Colon Cancer-A Case Report].
Topics: Aged; Anticoagulants; Colonic Neoplasms; Fluorouracil; Humans; Pulmonary Embolism; Pyridines; Thiazoles; Thromboembolism; Venous Thromboembolism | 2019 |
Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation Tests; Chromatography, Liquid; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Tandem Mass Spectrometry; Thiazoles; Venous Thromboembolism | 2020 |
Management of antithrombotic therapy in gray areas of venous thromboembolism: a Delphi consensus panel.
Topics: Administration, Oral; Delphi Technique; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Humans; Male; Pyridines; Thiazoles; Venous Thromboembolism; Warfarin | 2020 |
Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Anticoagulants; Asia; Comorbidity; Cross-Sectional Studies; Dabigatran; Diabetes Mellitus; Europe; Factor Xa Inhibitors; Female; Fondaparinux; Heparin; Humans; Hypertension; Latin America; Male; Middle Aged; Middle East; Neoplasms; Postoperative Complications; Practice Patterns, Physicians'; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis; Wounds and Injuries | 2020 |
Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial.
Topics: Anticoagulants; Factor Xa Inhibitors; Humans; Male; Pyridines; Thiazoles; Venous Thromboembolism; Warfarin | 2020 |
Venous thromboembolism and coronavirus disease 2019 in an ambulatory care setting - A report of 4 cases.
Topics: Adult; Ambulatory Care; Bed Rest; COVID-19; Factor Xa Inhibitors; Humans; Male; Middle Aged; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Factors; Thiazoles; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2020 |
ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries.
Topics: Anticoagulants; Europe; Factor Xa Inhibitors; Female; Humans; Prospective Studies; Pyridines; Thiazoles; Venous Thromboembolism | 2020 |
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months.
Topics: Aged; Anticoagulants; Europe; Female; Humans; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Pyridines; Risk Assessment; Thiazoles; Venous Thromboembolism | 2020 |
Edoxaban for the Long-Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?
Topics: Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Drug Tapering; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyridines; Recurrence; Registries; Thiazoles; Time Factors; Venous Thromboembolism | 2021 |
Edoxaban (LIXIANA
Topics: Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Venous Thromboembolism | 2021 |
Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Factor Xa Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyridines; Thiazoles; Venous Thromboembolism | 2021 |
[Periprocedural edoxaban interruption is associated with low bleeding and thromboembolic risk: the Italian data of the EMIT-AF/VTE study].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Hemorrhage; Humans; Italy; Pyridines; Stroke; Thiazoles; Venous Thromboembolism | 2021 |
Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2021 |
Antithrombotic Therapy for Venous Thromboembolic Disease.
Topics: Antithrombins; Dabigatran; Humans; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Review Literature as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis; Vitamin K | 2017 |
Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Dose-Response Relationship, Drug; Evidence-Based Medicine; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Is it reasonable to use a lower DOAC dose in some patients with VTE? NO.
Topics: Administration, Oral; Anticoagulants; Evidence-Based Medicine; Humans; Pyridines; Thiazoles; Venous Thromboembolism; Vitamin K | 2017 |
Prothrombin time-international normalized ratio is a useful marker for edoxaban efficacy in preventing venous thromboembolism after total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Biomarkers; Early Ambulation; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Postoperative Complications; Postoperative Period; Pre-Exposure Prophylaxis; Prospective Studies; Prothrombin Time; Pyridines; ROC Curve; Thiazoles; Ultrasonography, Doppler, Color; Venous Thromboembolism; Venous Thrombosis | 2018 |
Evaluation of Direct-Acting Oral Anticoagulant Use in Patients With Cancer.
Topics: Administration, Oral; Aged; Anticoagulants; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2018 |
Measuring Direct Oral Anticoagulants.
Topics: Administration, Oral; Antithrombins; Blood Coagulation; Dabigatran; Drug Monitoring; Endopeptidases; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombin Time; Venous Thromboembolism | 2017 |
Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels.
Topics: Acute Disease; Aged; Anticoagulants; Antithrombin III; Female; Humans; Male; Middle Aged; Protein C; Protein S; Pulmonary Embolism; Pyridines; Thiazoles; Treatment Outcome; Venous Thromboembolism; Warfarin | 2018 |
Prothrombin times in the presence of edoxaban - in-vivo experience from King's College hospital.
Topics: Anticoagulants; Female; Humans; Male; Prothrombin Time; Pyridines; Stroke; Thiazoles; United Kingdom; Venous Thromboembolism | 2019 |
Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage.
Topics: Aged; Anticoagulants; Carcinoma, Non-Small-Cell Lung; Heparin; Humans; Lung Neoplasms; Male; Pyridines; Thiazoles; Tumor Burden; Venous Thromboembolism; Warfarin | 2018 |
Edoxaban for the Treatment of Venous Thromboembolism in Patients with Cancer.
Topics: Administration, Oral; Anticoagulants; Factor Xa Inhibitors; Humans; Neoplasms; Pyridines; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2018 |
Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study.
Topics: Adult; Aged; Anticoagulants; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2018 |
Comparison of the effects of edoxaban, an oral direct factor Xa inhibitor, on venous thromboembolism between patients with and without cancer.
Topics: Aged; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Neoplasms; Pulmonary Embolism; Pyridines; Recurrence; Retrospective Studies; Thiazoles; Venous Thromboembolism | 2018 |
The clinical impact of edoxaban for the patients with postoperative anemia after total hip arthroplasty.
Topics: Aged; Aged, 80 and over; Anemia; Anticoagulants; Arthroplasty, Replacement, Hip; Blood Coagulation Tests; Chemoprevention; Factor Xa Inhibitors; Female; Fondaparinux; Humans; Male; Middle Aged; Predictive Value of Tests; Pyridines; Retrospective Studies; Thiazoles; Venous Thromboembolism | 2018 |
Abnormal vaginal bleeding in the 'DOAC' era.
Topics: Female; Humans; Pyridines; Thiazoles; Uterine Hemorrhage; Venous Thromboembolism; Warfarin | 2018 |
Edoxaban for the treatment of cancer associated venous thromboembolism as an alternative to low-molecular-weight-heparin.
Topics: Anticoagulants; Heparin; Heparin, Low-Molecular-Weight; Humans; Pyridines; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
Edoxaban for Cancer-Associated Venous Thromboembolism.
Topics: Administration, Oral; Anticoagulants; Factor Xa Inhibitors; Humans; Neoplasms; Pyridines; Thiazoles; Venous Thromboembolism | 2018 |
Edoxaban for Cancer-Associated Venous Thromboembolism.
Topics: Humans; Neoplasms; Pyridines; Thiazoles; Venous Thromboembolism | 2018 |
Edoxaban for Cancer-Associated Venous Thromboembolism.
Topics: Humans; Neoplasms; Pyridines; Thiazoles; Venous Thromboembolism | 2018 |
Edoxaban for Cancer-Associated Venous Thromboembolism.
Topics: Humans; Neoplasms; Pyridines; Thiazoles; Venous Thromboembolism | 2018 |
Edoxaban for Cancer-Associated Venous Thromboembolism.
Topics: Humans; Neoplasms; Pyridines; Thiazoles; Venous Thromboembolism | 2018 |
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Factor Xa Inhibitors; Hemorrhage; Humans; Multicenter Studies as Topic; Neoplasms; Observational Studies as Topic; Patient Acceptance of Health Care; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Survival Analysis; Thiazoles; Venous Thromboembolism; Warfarin | 2018 |
[Treatment of cancer-associated venous thromboembolism].
Topics: Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2018 |
Effectiveness and safety of oral direct factor Xa inhibitors for the treatment of venous thromboembolism in patients with cancer and/or older age.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Japan; Lower Extremity; Male; Middle Aged; Neoplasms; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2019 |
Topics: Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Neoplasms; Perioperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
[Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasms; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Severity of Illness Index; Thiazoles; Venous Thromboembolism | 2019 |
Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma: A case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Disease Progression; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Heparin; Humans; Intracranial Embolism; Lung Neoplasms; Middle Aged; Pyridines; Thiazoles; Venous Thromboembolism | 2019 |
A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
Topics: alpha-2-Antiplasmin; Anticoagulants; Blood Coagulation; Carboxypeptidase B2; Dose-Response Relationship, Drug; Fibrin Clot Lysis Time; Fibrinolysin; Fibrinolysis; Humans; Pyridines; Thiazoles; Tissue Plasminogen Activator; Venous Thromboembolism | 2019 |
Recurrent venous thrombosis during direct oral anticoagulant therapy in a patient with protein S deficiency.
Topics: Administration, Oral; Aged; Anticoagulants; Humans; Male; Protein S Deficiency; Pyrazoles; Pyridines; Pyridones; Recurrence; Thiazoles; Venous Thromboembolism | 2019 |
VTE and anti-coagulation therapy in cancer patients.
Topics: Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Dalteparin; Factor Xa Inhibitors; Humans; Neoplasms; Pyridines; Recurrence; Risk Factors; Secondary Prevention; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2019 |
Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Dose-Response Relationship, Drug; Enoxaparin; Female; Fondaparinux; Humans; Incidence; Knee Joint; Male; Osteoarthritis, Knee; Polysaccharides; Pyridines; Retrospective Studies; Thiazoles; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2014 |
Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Orthopedic Procedures; Pyridines; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism | 2013 |
New oral anticoagulants for acute venous thromboembolism.
Topics: Acute Disease; Anticoagulants; Benzimidazoles; Dabigatran; Drug Approval; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2014 |
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fees, Pharmaceutical; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Monte Carlo Method; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
New oral anticoagulants in the management of venous thromboembolism: a major advance?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Response to 'Re: Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trial
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2015 |
Re: 'Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2015 |
Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Costs and Cost Analysis; Dabigatran; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Myocardial Infarction; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; United States; Venous Thromboembolism; Warfarin | 2015 |
Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer.
Topics: Anticoagulants; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism | 2015 |
Edoxaban (Savaysa)--the fourth new oral anticoagulant.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Embolism; Humans; Pyridines; Stroke; Thiazoles; United States; United States Food and Drug Administration; Venous Thromboembolism | 2015 |
Re: 'Re. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-analysis of Phase III Trials'.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2015 |
Re: 'Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'- Key Learning Points fo
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2015 |
[Simplified therapy regimen receives recommendation for approval].
Topics: Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Embolism; Humans; Pyridines; Recurrence; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2015 |
The evolving role of dabigatran etexilate in clinical practice.
Topics: Antithrombins; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Dabigatran; Enoxaparin; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2015 |
[Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma].
Topics: Aged; Factor Xa Inhibitors; Female; Humans; Lenalidomide; Multiple Myeloma; Pyridines; Thalidomide; Thiazoles; Tomography, X-Ray Computed; Venous Thromboembolism | 2015 |
Improving evidence on anticoagulant therapies for venous thromboembolism in children: key challenges and opportunities.
Topics: Adult; Age Factors; Anticoagulants; Child; Child, Preschool; Clinical Trials as Topic; Dabigatran; Disease Management; Evidence-Based Medicine; Heparin, Low-Molecular-Weight; Humans; Infant; Multicenter Studies as Topic; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
Topics: Adult; Anticoagulants; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Venous Thromboembolism; Warfarin | 2015 |
Use of non-steroidal anti-inflammatory drugs correlates with the risk of venous thromboembolism in knee osteoarthritis patients: a UK population-based case-control study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Lactones; Logistic Models; Male; Meloxicam; Middle Aged; Naproxen; Odds Ratio; Osteoarthritis, Knee; Risk Factors; Sulfones; Thiazines; Thiazoles; Treatment Outcome; United Kingdom; Venous Thromboembolism | 2016 |
Edoxaban in the secondary prevention of VTE.
Topics: Anticoagulants; Humans; Pyridines; Secondary Prevention; Thiazoles; Venous Thromboembolism | 2016 |
[Venous Thromboembolism during the Cisplatin-based Adjuvant Chemotherapy;Report of a Case].
Topics: Anticoagulants; Chemotherapy, Adjuvant; Cisplatin; Drug Substitution; Drug Therapy, Combination; Echocardiography; Female; Fibrinolytic Agents; Fondaparinux; Humans; Lung Neoplasms; Middle Aged; Polysaccharides; Pyridines; Thiazoles; Thrombolytic Therapy; Tomography, X-Ray Computed; Treatment Outcome; Urokinase-Type Plasminogen Activator; Venous Thromboembolism | 2016 |
Direct oral anticoagulants and cancer: no swansong yet for the low-molecular-weight heparins.
Topics: Anticoagulants; Double-Blind Method; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyridines; Thiazoles; Venous Thromboembolism | 2016 |
Edoxaban for pulmonary embolism with right ventricular dysfunction.
Topics: Humans; Pulmonary Embolism; Pyridines; Thiazoles; Venous Thromboembolism; Ventricular Dysfunction, Right | 2016 |
Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Hormone Replacement Therapy; Humans; Menorrhagia; Middle Aged; Progesterone; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Uterine Hemorrhage; Venous Thromboembolism | 2016 |
Italian intersociety consensus on DOAC use in internal medicine.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Competence; Consensus; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Factor Xa Inhibitors; Food-Drug Interactions; Humans; Internal Medicine; Italy; Liver Diseases; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Time Factors; Venous Thromboembolism | 2017 |
Factor Xa and thrombin as targets for new oral anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K | 2011 |
[New anticoagulants in the prevention and treatment of venous thromboembolism].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Costs; Drugs, Investigational; Factor Xa Inhibitors; Humans; Hungary; Morpholines; Oligosaccharides; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism | 2011 |
Edoxaban: pharmacological principles, preclinical and early-phase clinical testing.
Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Venous Thromboembolism | 2011 |